"Co-Diagnostics, Inc. reported a second-quarter 2025 EPS loss of $0.23, which beat estimates, while revenue of $0.2 million exceeded expectations, indicating some operational resilience. However, the overall sentiment remains negative, reflecting ongoing risks related to market conditions and the company's financial performance."